Eligibility criteria
HEMATOLOGIC MALIGNANCY, SOLID TUMORS
Key inclusion criteria included patients with advanced solid tumors (not hematologic malignancy), either relapsed after standard therapy or without standard therapy available. Patients must have had one of the following pre-identified somatic molecular aberrations predicted to be activating or pathogenic as performed in the Clinical Laboratory Improvement Amendments (CLIA) environment and suitable for enrollment: 